Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 741 participants.
Also called NCT01164501
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 741 participants
- Registry
-
NCT01164501 -
2009-016179-31
-
- Other papers using this trial's data
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, France, Hong Kong SAR China, India, Malaysia, Netherlands, Philippines, Poland, Portugal, Russia, Slovakia, South Africa, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01164501. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-07 (actual). Results posted on 2014-06-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Renal Insufficiency
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01164501- Content hash
bb7f98a9f3b338b1c378ce4b16a2aa1c113ac1c3b77508114972906a2b944c72